Navigation Links
Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C
Date:6/8/2009

ase. The company's proprietary Leumeta(TM) portfolio of tests helps physicians identify and analyze genetic components of leukemia and lymphoma tumors using blood plasma instead of bone marrow, which can only be tested after extraction through painful biopsy. In addition, the company is the exclusive national reference laboratory provider of the blood-based HE4 Ovarian Cancer Monitoring test, which is FDA-cleared as an aid in monitoring epithelial ovarian cancer. The company is also developing a molecular blood test based on Epigenomics AG's Septin 9 DNA methylation biomarker that can help physicians detect colorectal cancer based on a patient's blood specimen.

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at www.questdiagnostics.com.

(1) AUROC is a graphic representation of test results that indicates a test's overall performance based on sensitivity and specificity, with a score up to 1.0. The closer a test scores to 1.0, the more accurate its performance.


'/>"/>
SOURCE Quest Diagnostics Incorporated
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... (NYSE: MOS ) plans to issue its ... tables on Tuesday, January 5, 2010, after the close ... Results will be available on Mosaic,s website at mosaicco.com/investors. ... call with presentation slides on Wednesday, January 6, 2010, ... at 11:00 a.m. Eastern Standard Time (10:00 a.m. Central ...
(Date:12/15/2009)... Belgium, December 15 , ... Designed to Evaluate the Ability of,Cardiopoietic Cells to ... Cardio3 BioSciences, a leading Belgian biotechnology company specialising,in ... today that it has completed, two months ahead ... pivotal Phase II/III trial of C-Cure, a,unique stem ...
(Date:12/14/2009)... Patrick Kennedy Joins with State Biotech Leaders ... in Research and Development while Boosting Rhode ... ,, PROVIDENCE, R.I., Dec. 14 /PRNewswire-USNewswire/ ... leaders in research, medicine and biotechnology gathered ... to discuss the importance of medical innovation ...
(Date:12/14/2009)... WALTHAM, Mass., Dec. 14 Decision Resources, ... firms for pharmaceutical and healthcare issues, finds that, ... the atrial fibrillation drug market will increase more ... $6.1 billion in 2018 in the United States, ... Japan. ,, The new Pharmacor report entitled ...
Breaking Biology Technology:Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2
... at the 2008 Genitourinary Cancers Symposium, ... Inc. announced,today that the Company,s lead cancer ... was well-tolerated in combination with either docetaxel ... with,hormone refractory prostate cancer. Additionally, patients treated ...
... Testing the safety of chemicals ranging from pesticides to ... plan for collaboration, according to federal scientists from the ... Protection Agency (EPA), who today announced a new toxicity ... in the Feb. 15, 2008 issue of the journal ...
... summary of the National Nanotechnology Initiative (NNI) Fiscal Year ... Engineering, and Technology (NSET) Subcommittee of the National Science ... a supplement to the Presidents Budget for Fiscal Year ... as well as highlights of planned activities to be ...
Other Biology Technology:OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer 2OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer 3OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer 4NIH collaborates with EPA to improve the safety testing of chemicals 2NIH collaborates with EPA to improve the safety testing of chemicals 3National Nanotechnology Initiative releases its fiscal year 2009 budget and highlights 2
(Date:12/14/2009)... Nations Framework Convention on Climate Change taking place ... ,Bend the Trend, event on Sunday evening to ... the screening of the new ,Environmental Atlas of ... joint project of the European Environment Agency (EEA), ... a series of short films showing the significance ...
(Date:12/13/2009)... enzymes that may help to engineer plants that take ... efficiently. The finding could help to engineer crops that ... in the carbon dioxide they need for photosynthesis through ... for each molecule of the gas gained, they lose ... pores can tighten to save water when CO 2 ...
(Date:12/13/2009)... five genetic variants that are associated with the health ... consortium of 96 scientists from 63 centres in Europe ... of lung diseases. , The new findings provide hope ... Pulmonary Disease (COPD) and asthma. In the past it ... molecular pathways that affect the health of the lung ...
Breaking Biology News(10 mins):'Environmental Atlas of Europe' unveiled at COP15 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 3New genes for lung disease discovered 2New information about how fat increases blood pressure could help identify those at risk 9752 1New information about how fat increases blood pressure could help identify those at risk 9752 2New information about how fat increases blood pressure could help identify those at risk 9752 3International event brings worlds top cancer doctors to Queens 9750 1International event brings worlds top cancer doctors to Queens 9750 2International event brings worlds top cancer doctors to Queens 9750 3Hard To Treat Diseases 28HTDS PK 29 Stem Cells and Regenerative Medicine 4931 1Hard To Treat Diseases 28HTDS PK 29 Stem Cells and Regenerative Medicine 4931 2Hard To Treat Diseases 28HTDS PK 29 Stem Cells and Regenerative Medicine 4931 3
... Dr Karen Beemon has been awarded the third annual Retrovirology ... crystal trophy and is interviewed in an article published today ... Chair of the Biology Department, Johns Hopkins University. , ... It is wonderful to be recognized by the ...
... energy source and use up carbon dioxide in the process, ... briefing today. , Methanogens are microbes called archaea that are ... of methane produced on earth by living things says Dr ... methane, the major flammable component of natural gas. So methanogens ...
... Raton, FL, December 8, 2007 Brain overgrowth in ... contribute to the onset of autistic characteristics, according to ... (ACNP) annual meeting. These findings support concurrent research which ... as two years old. , Lead researcher Joseph Piven, ...
Other Biology News:Karen Beemon wins the 2007 Retrovirology Prize 2New studies suggest brain overgrowth in 1-year-olds linked to development of autism 2
Purified anti-eIF-4E...
Polyclonal Antibody to CLAN...
Polyclonal Antibody to PRG3...
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
Biology Products: